Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

anacetrapib

- PMLiVE

Merck’s hep C drug no longer a ‘breakthrough’

FDA rescinds designation for grazoprevir/elbasvir due to approval of other treatments

Sanofi reception

Monthly dosing effective for Sanofi’s alirocumab

New data puts pressure on Amgen's evolocumab

- PMLiVE

Ebola vaccine halt ‘a precaution’ say researchers

Some patients have reported joint pains

- PMLiVE

Merck to start major trial of Keytruda in breast cancer

PD-1 immunotherapy is already available as treatment for melanoma

- PMLiVE

PD-1 inhibitors shine at ASH conference

New data suggests the immunotherapy class could be also used for haematological cancers

- PMLiVE

PCSK9 inhibitor alirocumab works in statin-intolerance

Sanofi and Regeneron’s drug impresses at American Heart Association meeting

- PMLiVE

FDA to review Amgen’s cholesterol drug

US regulator accepts first in new class of PCSK9 inhibitors

- PMLiVE

Amgen submits melanoma and cholesterol drugs to EMA

Regulator will assess talimogene laherparepvec and evolocumab

- PMLiVE

Amgen claims first-to-file spot in PCSK9 inhibitor race

Evolocumab is part of new class of treatment to tackle high cholesterol

- PMLiVE

MSD’s Kate Tillett rewarded for healthcare comms excellence

Company's external affairs director wins at Communiqué 2014

- PMLiVE

ADA: Merck launches registry for type 2 diabetes

Will collect information from 20,000 patients across four countries

- PMLiVE

Merck’s first-in-class Zontivity cleared in US

FDA approves the protease-activated receptor-1 antagonist to reduce heart attack risk

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links